Epicutaneous/transcutaneous allergen-specific immunotherapy: Rationale and clinical trials

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 6, 2010, Pages 582-586

  Senti, Gabriela ^a   Freiburghaus, Andreas U ^a   Kundig, Thomas M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

allergy; desensitization; epicutaneous immunotherapy; transcutaneous immunotherapy

Indexed keywords

ALLERGEN; BACTERIAL TOXIN; CHOLERA TOXIN; IMMUNOGLOBULIN E; POLLEN ANTIGEN; RECOMBINANT ANTIGEN;

CLINICAL TRIAL; DESENSITIZATION; EPICUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INFLUENZA VACCINATION; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SAFETY; TRANSDERMAL DRUG ADMINISTRATION; VACCINATION;

ADMINISTRATION, CUTANEOUS; ALLERGENS; ANIMALS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; EPIDERMIS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE TOLERANCE;

EID: 78449242330     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833f1419     Document Type: Review

References (62)

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC The Interna-tional Study of Asthma and Allergies in Childhood (ISAAC) Steering Com-mittee. Lancet 1998; 351:1225-1232.
2. Arbes SJ Jr, Gergen PJ, Elliott L, et al. Prevalences of positive skin test responsesto 10common allergens intheUS population: resultsfromthethird National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116:377-383.
3. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy ofgrass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
4. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-948.
5. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991; 302:265-269.
6. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol 1998; 102 (4 Pt 1):558-562.
7. Lockey RF. 'ARIA': global guidelines and new forms of allergen immunother-apy. J Allergy Clin Immunol 2001; 108:497-499.
8. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immu-notherapy: asix-yearfollow-up study. Clin Exp Allergy 2001; 31:1392-1397.
9. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256.
10. ALK-Abelló. Epidemiology surveys and danske equities. Hørsholm, Denmark: ALK-Abelló; 2005.
11. Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunother-apy. J Allergy Clin Immunol 1992; 90 (4 Pt 1):567-578.
12. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-771.
13. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev 2009; 8:645-660.
14. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004; 113:1013-1023; quiz 1024.
15. Till SJ, Francis JN, Nouri-Aria K, et al. Mechanismsofimmunotherapy. JAllergy Clin Immunol 2004; 113:1025-1034; quiz 1035.
16. Pierson-Mullany LK, Jackola D, Blumenthal M, et al. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 2000; 84:241-243.
17. Kundig TM, Bachmann MF. Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG? Hum Vaccin 2010; 6.
18. Glenn GM, Kenney RT, Hammond SA, et al.Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 2003; 23:787-813.
19. Flacher V, Sparber F, Tripp CH, et al.Targeting of epidermal Langerhanscells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother 2009; 58:1137-1147.
20. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patchesfor influenzavaccination. Nat Med 2010; 16:915-920.
21. Kenney RT, Yu J, Guebre-Xabier M, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004; 190:774-782.
22. Hammond SA, Walwender D, Alving CR, et al. Transcutaneous immunization: Tcell responsesand boosting ofexisting immunity.Vaccine 2001; 19:2701-2707.
23. Partidos CD, Beignon AS, Semetey V, et al. The bare skin and the nose as noninvasive routes for administering peptide vaccines. Vaccine 2001; 19:2708-2715.
24. Romani N, Koide S, Crowley M, et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989; 169:1169-1178.
25. Celluzzi CM, Falo LD Jr. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 1997; 108:716-720.
26. Bergstresser PR, Fletcher CR, Streilein JW. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol 1980; 74:77-80.
27. Saloga J, Renz H, Larsen GL, et al. Increased airways responsiveness in mice depends on local challenge with antigen. Am J Respir Crit Care Med 1994; 149:65-70.
28. Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992; 175:1285-1290.
29. Wang B, Rieger A, Kilgus O, et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J Exp Med 1992; 175:1353-1365.
30. Sager N, Feldmann A, Schilling G, et al. House dust mite-specific T cells in the skin ofsubjectswith atopicdermatitis:frequencyand lymphokine profile in the allergen patchtest. J Allergy Clin Immunol 1992; 89:801-810.
31. Stoitzner P, Sparber F, Tripp CH. Langerhans cells as targets for immu-notherapy against skin cancer. Immunol Cell Biol 2010; 88:431-437.
32. Frerichs DM, Ellingsworth LR, Frech SA, et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 2008; 26:2782-2787.
33. Bashir SJ, Chew AL, Anigbogu A, et al. Physical and physiological effects of stratum corneum tape stripping. Skin Res Technol 2001; 7:40-48.
34. Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a domi-nant systemic Th2 response. Eur J Immunol 2004; 34:2100-2109.
35. Wang B, Feliciani C, Howell BG, et al. Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 2002; 168:3303-3308.
36. Hauser C, Saurat JH, Schmitt A, et al. Interleukin 1 is present in normal human epidermis.JImmunol 1986; 136:3317-3323.
37. Camp R, Fincham N, Ross J, et al. Potent inflammatory properties in human skin of interleukin-1 alpha-like material isolated from normal skin. J Invest Dermatol 1990; 94:735-741.
38. Corsini E, Galli CL. Epidermal cytokines in experimental contact dermatitis. Toxicology2000; 142:203-211.
39. Inoue J, Yotsumoto S, Sakamoto T, et al. Changes in immune responses to antigen applied totape-stripped skin with CpG-oligodeoxynucleotide in mice. J Controlled Release 2005; 108:294-305. (Pubitemid 41608662)
40. Inoue J, Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG- oligodeoxynucleotides. Vaccine 2007; 25:1007-1013.
41. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19:37-44.
42. Cumberbatch M, Dearman RJ, Antonopoulos C, et al. Interleukin (IL)-1 8 induces Langerhans cell migration by a tumour necrosis factor-alpha-and IL-1beta-dependent mechanism. Immunology 2001; 102:323-330.
43. Hunziker T, Brand CU, Kapp A, et al. Increased levels of inflammatory cytokines in human skin lymph derived from sodium lauryl sulphate-induced contactdermatitis. Br J Dermatol 1992; 127:254-257.
44. Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin. Nature 1998; 391:851.
45. Glenn GM, Scharton-Kersten T, Vassell R, et al.Transcutaneousimmunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67:1100-1106.
46. Glenn GM, Scharton-Kersten T, Vassell R, et al.Transcutaneousimmunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161:3211-3214.
47. Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specificThelpertype 1 (Th1)toTh2-type responses. Immunology 2006; 119:27-35.
48. Frech SA, Kenney RT, Spyr CA, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005; 23:946-950.
49. Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019-2025.
50. Pautrizel R, Cabanieu G, Bricaud H, et al. Allergenic group specificity and therapeutic consequences in asthma: specific desensitization method by epicutaneous route. La semaine des hopitaux 1957; 33:1394-1403.
51. Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med 1959; 67:2299-2301.
52. Eichenberger H, Storck H. Co-seasonal desensitization of pollinosis with the scarification method of Blamoutier. Acta Allergol 1965; XXI:261-267.
53. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen admin-istration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008; 105:17908-17912.
54. Martinez-Gomez JM,Johansen P, Erdmann I, et al. Intralymphatic injectionsas a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009; 150:59-65.
55. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124:997-1002.
56. Werfel T. Epicutaneousallergen administration: anovelapproachforallergen- specific immunotherapy? J Allergy Clin Immunol 2009; 124:1003-1004.
57. Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40:659-667.
58. Soury D, Barratt G, Ah-Leung S, et al. Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test. Pharm Res 2005; 22:1530-1536.
59. Dupont C, Kalach N, Soulaines P, et al. Cow's milk epicutaneous immu-notherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125:1165-1167.
60. Agostinis F, Forti S, Di Berardino F. Grasstranscutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010; 65:410-411.
61. Su X, Kim BS, Kim SR, et al. Layer-by-layer-assembled multilayer films for transcutaneous drug and vaccine delivery. ACS Nano 2009; 3:3719-3729.
62. Mattheolabakis G, Lagoumintzis G, Panagi Z, et al.Transcutaneousdelivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010; 385:187-193.